Voyager Therapeutics (NASDAQ:VYGR) Stock Price Down 3.7%

Voyager Therapeutics, Inc. (NASDAQ:VYGR) shares traded down 3.7% during trading on Thursday . The company traded as low as $7.26 and last traded at $7.29. 90,007 shares changed hands during trading, a decline of 90% from the average session volume of 898,971 shares. The stock had previously closed at $7.57.

Wall Street Analysts Forecast Growth

VYGR has been the topic of several analyst reports. Citigroup began coverage on shares of Voyager Therapeutics in a report on Thursday, March 7th. They issued a “buy” rating and a $16.00 price objective on the stock. Wells Fargo & Company upgraded shares of Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $9.00 to $14.00 in a report on Tuesday, January 2nd. HC Wainwright began coverage on shares of Voyager Therapeutics in a report on Tuesday, March 19th. They issued a “buy” rating and a $30.00 target price on the stock. StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, March 9th. Finally, Guggenheim began coverage on shares of Voyager Therapeutics in a report on Tuesday, March 26th. They issued a “buy” rating and a $22.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $19.33.

Voyager Therapeutics Price Performance

The firm has a market cap of $402.91 million, a P/E ratio of 2.40 and a beta of 0.96. The business’s 50-day moving average is $8.81 and its two-hundred day moving average is $7.96.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $1.84. The business had revenue of $90.06 million during the quarter, compared to the consensus estimate of $4.95 million. Voyager Therapeutics had a net margin of 52.93% and a return on equity of 63.89%. Equities research analysts predict that Voyager Therapeutics, Inc. will post -1.64 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in VYGR. Armistice Capital LLC grew its position in Voyager Therapeutics by 15.3% in the third quarter. Armistice Capital LLC now owns 4,178,000 shares of the company’s stock valued at $32,380,000 after purchasing an additional 554,000 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in shares of Voyager Therapeutics in the 4th quarter valued at about $1,569,000. Kestra Advisory Services LLC bought a new position in shares of Voyager Therapeutics in the 3rd quarter valued at about $980,000. Massachusetts Financial Services Co. MA bought a new position in shares of Voyager Therapeutics in the 3rd quarter valued at about $887,000. Finally, Inspire Investing LLC bought a new position in shares of Voyager Therapeutics in the 3rd quarter valued at about $641,000. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.